K
Kavitha Goyal
Researcher at Janssen Pharmaceutica
Publications - 29
Citations - 1181
Kavitha Goyal is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Psoriasis & Ustekinumab. The author has an hindex of 13, co-authored 29 publications receiving 989 citations.
Papers
More filters
Journal ArticleDOI
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Robert E. Kalb,David Fiorentino,Mark Lebwohl,John Toole,Yves Poulin,Arnon D. Cohen,Kavitha Goyal,Steven Fakharzadeh,S. Calabro,Marc Chevrier,Wayne Langholff,Yin You,Craig L. Leonardi +12 more
TL;DR: Results from PSOLAR suggest a higher risk of serious infections with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.
Journal ArticleDOI
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Alan Menter,Kim A. Papp,Melinda Gooderham,David M. Pariser,Matthias Augustin,Francisco A. Kerdel,Steven Fakharzadeh,Kavitha Goyal,S. Calabro,Wayne Langholff,S. Chavers,D. Naessens,J. Sermon,Gerald G. Krueger +13 more
TL;DR: Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis and it is important to know whether the drug is still available for use in the future.
Journal ArticleDOI
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
David Fiorentino,Vincent T. Ho,Mark Lebwohl,Luiz Leite,Lori Hopkins,Claudia Galindo,Kavitha Goyal,Wayne Langholff,Steven Fakharzadeh,Bhaskar Srivastava,Richard G. Langley +10 more
TL;DR: Long‐term treatment with a TNF‐&agr; inhibitor, but not methotrexate and ustekinumab, may increase risk for malignancy in patients with psoriasis.
Journal ArticleDOI
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)*
Alexa B. Kimball,Craig L. Leonardi,Mona Ståhle,Wayne Gulliver,Marc Chevrier,Steven Fakharzadeh,Kavitha Goyal,S. Calabro,Wayne Langholff,Alan Menter +9 more
TL;DR: Psoriasis is associated with several comorbidities and behavioural risk factors and it is important to select patients suitable for surgery based on prior history and once they are diagnosed with Psoriasis.
Journal Article
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies
Alice B. Gottlieb,Robert E. Kalb,Richard G. Langley,Gerald G. Krueger,de Jong Em,Lyn Guenther,Kavitha Goyal,Steven Fakharzadeh,Marc Chevrier,S. Calabro,Wayne Langholff,Alan Menter +11 more
TL;DR: Based on PSOLAR data through 2013, no new safety concerns were observed with infliximab for all-cause mortality, MACE, or malignancy; the data suggest that inflIXimab was associated with serious infections.